Aytu Biopharma Inc expected to post a loss of 58  cents a share - Earnings Preview

Aytu Biopharma

08/02/2022 03:03

* Aytu Biopharma Inc  AYTU.OQ   AYTU.O  is expected to show
a rise
in quarterly revenue when it reports  results on February 9
(estimated). 
    * The Englewood Colorado-based  company is expected to
report  a
79.6% increase in revenue to $27.2 million from $15.15 million a
year ago, according to the estimate from one analyst, based on
Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Aytu Biopharma Inc
is for
a loss of 58 cents per share. For the same quarter last year,
the company reported a loss of 70 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aytu
Biopharma
Inc is $17.5​, about 92.8% above​ its last closing price
of $1.26. ​​​

This summary was machine generated February 8 at 03:03 GMT.  All
figures in US dollars  unless otherwise stated